Cerulean Pharma targets up to $75M from IPO to advance cancer drug

03/11/2014 | Xconomy

Cerulean Pharma hopes to raise up to $75 million in an initial public offering. The firm will use most of the money to support ongoing clinical trials of its nanoparticle-based cancer drug CRLX101 in patients with rectal, kidney and ovarian cancers despite previous setback in a lung cancer trial.

View Full Article in:

Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC